AveXis (AVXS) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada reaffirmed their hold rating on shares of AveXis (NASDAQ:AVXS) in a research report report published on Tuesday morning. The brokerage currently has a $92.00 target price on the stock.

A number of other research firms have also weighed in on AVXS. Citigroup set a $132.00 price objective on AveXis and gave the company a buy rating in a research report on Friday, January 5th. Canaccord Genuity set a $110.00 price objective on AveXis and gave the company a hold rating in a research report on Wednesday, December 20th. BidaskClub lowered AveXis from a hold rating to a sell rating in a research report on Thursday, December 14th. Bank of America reduced their price objective on AveXis from $115.00 to $112.00 and set a buy rating for the company in a research report on Friday, November 10th. Finally, BMO Capital Markets reaffirmed an outperform rating and set a $130.00 price objective (up previously from $123.00) on shares of AveXis in a research report on Thursday, October 12th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $111.67.

AveXis (AVXS) opened at $117.50 on Tuesday. AveXis has a 52-week low of $50.56 and a 52-week high of $119.00. The stock has a market capitalization of $3,720.14, a P/E ratio of -21.06 and a beta of 2.46.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the company earned ($0.87) earnings per share. equities analysts anticipate that AveXis will post -6.23 earnings per share for the current year.

In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $109.75, for a total value of $1,646,250.00. Following the completion of the sale, the insider now owns 1,808,386 shares of the company’s stock, valued at approximately $198,470,363.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $109.72, for a total value of $195,301.60. Following the completion of the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $195,301.60. The disclosure for this sale can be found here. In the last three months, insiders sold 52,340 shares of company stock valued at $5,318,845. Corporate insiders own 18.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in AVXS. Schwab Charles Investment Management Inc. boosted its stake in shares of AveXis by 57.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 86,520 shares of the company’s stock worth $7,109,000 after buying an additional 31,655 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of AveXis by 234.5% in the 2nd quarter. Rhumbline Advisers now owns 22,682 shares of the company’s stock worth $1,864,000 after buying an additional 15,901 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of AveXis by 28.2% in the 2nd quarter. SG Americas Securities LLC now owns 5,111 shares of the company’s stock worth $420,000 after buying an additional 1,124 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of AveXis by 79.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 113,225 shares of the company’s stock worth $9,302,000 after buying an additional 50,303 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of AveXis by 303.9% in the 2nd quarter. Legal & General Group Plc now owns 5,828 shares of the company’s stock worth $478,000 after buying an additional 4,385 shares during the last quarter. Hedge funds and other institutional investors own 92.88% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/13/avexis-avxs-rating-reiterated-by-royal-bank-of-canada.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit